Open Access

Probiotics do not significantly reduce nosocomial pneumonia

  • Luciano Silvestri1Email author,
  • Hendrick KF van Saene2 and
  • Dario Gregori3
Critical Care201216:453

DOI: 10.1186/cc11654

Published: 5 November 2012

Liu and colleagues, in their recent meta-analysis, concluded that probiotics were associated with a statistically significant reduction in the incidence of nosocomial pneumonia (NP) (odds ratio = 0.75; 95% confidence interval = 0.57 to 0.97, P = 0.03) [1]. These results were obtained using the fixed-effect model, ignoring a moderate level of heterogeneity (I2 = 46%) [2]. However, we believe that the inclusion criteria, subjects, and interventions were different among the included studies, and might have impacted the results. Good practice would therefore be to choose a more conservative analysis; that is, the random-effects model. Using this model, the claimed reduction in NP would have been not significant (odds ratio = 0.70, 95% confidence interval = 0.46 to 1.05, P = 0.085) (Figure 1). We have already addressed this issue with reference to a previous meta-analysis on probiotics [3, 4].
https://static-content.springer.com/image/art%3A10.1186%2Fcc11654/MediaObjects/13054_2012_Article_760_Fig1_HTML.jpg
Figure 1

Forrest plot for the impact of probiotics on nosocomial pneumonia. Results presented as the odds ratio (OR) with 95% confidence interval (CI) using the random-effects model. OR < 1 favors treatment; OR > 1 favors controls. Heterogeneity was not demonstrated (χ2 = 10.4158, degrees of freedom = 11, P = 0.49; I2 = 0%). The Cochran Q statistic for heterogeneity was used. Heterogeneity was considered significant if P < 0.10. I2 was evaluated with the formula 100%×(Q - df)/Q, where Q = Cochran Q statistic and df = degrees of freedom (number of studies - 1). Negative values of I2 are set equal to 0%. I2 = 0%, no observed heterogeneity; I2 < 40%, mild heterogeneity; I2 = 30 to 60%, moderate heterogeneity; I2 = 50 to 90%, substantial heterogeneity; and I2 = 75 to 90%, considerable heterogeneity [2]. τ 2 = 0.20425; heterogeneity before taking τ 2 into consideration was moderate (χ2 = 20.0232, degrees of freedom = 11, P = 0.045; I2 = 45.06%). References to studies are included in [1].

Remarkably, the authors used the random-effects model only when the I2 test for heterogeneity was higher than 50%. However, the strategy of starting with a fixed-effect model and subsequently moving to a random-effects model if the heterogeneity test is significant is discouraged by some authors [5]. The selection of a model should be based solely on the issue of which model fits the distribution of the effect sizes and takes into account the relevant sources of error.

In conclusion, this meta-analysis showed that probiotics did not significantly reduce NP. Additionally, ventilator-associated pneumonia and mortality were not impacted. The use of probiotics to reduce these important outcomes is therefore not justified given the low level of evidence.

Authors' response

Kai-xiong Liu, Ying-gang Zhu, Jing Zhang, Li-li Tao, Jae-Woo Lee, Xiao-dan Wang and Jie-ming Qu

We thank Dr Silvestri and colleagues for their interest in our meta-analysis regarding the potential effect of probiotics for the prevention of NP [1].

Silvestri and colleagues noted that a more conservative random-effects model should be used to analyze the pooled incidence of NP. The reason why we used a fixed-effect model in our analysis can be explained by the lack of statistical power. The confidence intervals tend to be wider especially when implementing a random-effects model, and the statistical significance is more likely to be lost. Regarding the potential misinterpretation among the special patient population in our review that is different from other studies [4, 6], we predefined heterogeneity as low, moderate or high with I2 values above 25%, 50%, and 75%, respectively, as recommended by some authors [7]. We calculated all pooled odds ratios based on this criterion to increase the consistency of our meta-analysis.

Silvestri and colleagues are also concerned about the switch between different models. However, our population of critically ill patients, as we mentioned above, is from a heterogenetic group. Heterogeneity is an inevitable issue in studies on critical care. Using different models depending on heterogeneity [7] is supposed to be a more conservative way to interpret the results.

Despite the potential limitations of our work [1], we believe the available evidence suggests that probiotics have a marginal effect on the prevention of NP, and relevant research should not be discouraged to identify populations that benefit most from probiotics. We fully agree with Dr Silvestri and colleagues that further large-scale, randomized controlled trials are warranted. This was also clearly stated in the conclusions of our meta-analysis.

Abbreviations

NP: 

nosocomial pneumonia.

Declarations

Authors’ Affiliations

(1)
Department of Emergency, Unit of Anesthesia and Intensive Care, Presidio Ospedaliero
(2)
Institute of Ageing and Chronic Disease, University of Liverpool
(3)
Department of Cardiological, Thoracic and Vascular Sciences, Unit of Biostatistics, Epidemiology and Public Health, University of Padova

References

  1. Liu K, Zhu Y, Zhang J, Tao L, Lee J, Wang X, Qu J: Probiotics' effects on the incidence of nosocomial pneumonia in critically ill patients: a systematic review and meta-analysis. Crit Care. 2012, 16: R109-10.1186/cc11398.PubMed CentralView ArticlePubMed
  2. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions. 2011, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration;, [http://​www.​cochrane-handbook.​org]
  3. Silvestri L, van Saene HKF, Gregori D, Agostini S, Francescon M, Taylor N: Probiotics to prevent ventilator-associated pneumonia: no robust evidence from randomized controlled trials. Crit Care Med. 2010, 38: 1616-1617. 10.1097/CCM.0b013e3181dd0a67.View ArticlePubMed
  4. Siempos II, Ntaidou TK, Falagas ME: Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med. 2010, 38: 954-962. 10.1097/CCM.0b013e3181c8fe4b.View ArticlePubMed
  5. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: Introduction to Meta-analysis. 2009, Padstow: TJ International, John Wiley & Sons LtdView Article
  6. Gu WJ, Wei CY, Yin RX: Lack of efficacy of probiotics in preventing ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. Chest. 2012, Epub ahead of print
  7. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003, 327: 557-560. 10.1136/bmj.327.7414.557.PubMed CentralView ArticlePubMed

Copyright

© BioMed Central Ltd 2012

Advertisement